SCHEMBL3465646

SCHEMBL3465646

NC(=O)c1ccc(N2CCCC2=O)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.51
ALDH1A1 P00352 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
NNMT P40261 1/20 0.47
PARP1 P09874 2/20 0.44
OPRM1 P35372 2/20 0.44
OPRK1 P41145 1/20 0.44
HPGD P15428 4/20 0.43
UBE2T Q9NPD8 1/20 0.43
OPRL1 P41146 1/20 0.42
HPGDS O60760 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42
HRH3 Q9Y5N1 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16753459 0.85 CNR2 (0.51) CNR2ALDH1A1SMN1; SMN2PARP1HPGD
SCHEMBL7432940 0.81 CNR2 (0.53) CNR2ALDH1A1SMN1; SMN2PARP1HPGD
SCHEMBL14910345 0.80 CNR2 (0.53) CNR2ALDH1A1PARP1KLKB1KLK1
SCHEMBL2645643 0.78 CNR2 (0.56) CNR2ALDH1A1PARP1HPGDHPGDS
SCHEMBL29475033 0.76 UBE2T (0.71) ALDH1A1SMN1; SMN2NNMTPARP1OPRM1
SCHEMBL4418893 0.76 ALDH1A1 (0.75) ALDH1A1SMN1; SMN2HPGDNPC1POLB
SCHEMBL30289763 0.76 UBE2T (0.71) ALDH1A1SMN1; SMN2NNMTPARP1OPRM1
SCHEMBL46340 0.75 CNR2 (0.52) CNR2ALDH1A1PARP1
Hydrochloric Acid SCHEMBL5010433 0.75 UBE2T (0.69) ALDH1A1SMN1; SMN2NNMTPARP1OPRM1
SCHEMBL77785 0.75 CNR2 (0.49) CNR2ALDH1A1PARP1HPGDKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 US disclosed
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 CNR2 54/4885ALDH1A1 523/4885SMN1; SMN2 1172/4885
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 CNR2 46/4885ALDH1A1 268/4885SMN1; SMN2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.